Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas

Trial Profile

Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Feb 2019

At a glance

  • Drugs Aglatimagene besadenovec (Primary) ; Nivolumab (Primary) ; Temozolomide (Primary) ; Valaciclovir (Primary)
  • Indications Glioma
  • Focus Adverse reactions; First in man; Proof of concept
  • Most Recent Events

    • 07 Feb 2019 Status changed from active, no longer recruiting to recruiting.
    • 04 Jan 2019 According to a Candel Therapeutics media release, the company had received the Series B financing from PBM Capital Group, to Advance its late-stage high-grade glioma program that includes which includes this study and NCT03152318 study.
    • 10 Jul 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top